Share on LinkedInShare on LinkedIn

ARTICLE · 29 MAY 2019

AI-Driven Products Require New Ways Of Approaching Regulation

Gowling WLG
Gowling WLG
Contributor
Gowling WLG

Gowling WLG

The firm The firm’s lawyers speak English, French, Russian and Ukrainian. The firm’s client base...

View firm profile
Explore more from Gowling WLG

As private enterprise and government alike continue to explore the promise and challenges of artificial intelligence (AI)-driven products proliferating the marketplace ...

CanadaTechnology

As private enterprise and government alike continue to explore the promise and challenges of artificial intelligence (AI)-driven products proliferating the marketplace, regulation has — not surprisingly — emerged as a top concern. 

What's becoming increasingly clear is that such products will not only require new regulations, but a completely different approach to regulatory approvals altogether — one that complements standard pre-market approvals with a comprehensive total product life-cycle monitoring process.

The U.S. Food and Drug Administration recently issued a press release and discussion paper proposing just such a framework for AI-based medical devices. In particular, the agency wants to explore continuously learning or adaptive algorithms, rather than ones that have been locked (and approved).

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from